Smith & Nephew (LON:SN) Downgraded to “Sector perform” Rating by Royal Bank Of Canada

Smith & Nephew (LON:SN) was downgraded by Royal Bank Of Canada to a “sector perform” rating in a research note issued on Thursday,Digital Look reports. They presently have a GBX 1,350 target price on the stock. Royal Bank Of Canada’s price target points to a potential upside of 16.48% from the stock’s current price.

Other analysts also recently issued research reports about the company. Berenberg Bank restated a “hold” rating and issued a GBX 13 target price on shares of Smith & Nephew in a research report on Friday, May 1st. UBS Group restated a “neutral” rating and set a GBX 1,300 target price on shares of Smith & Nephew in a report on Tuesday. Two equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of GBX 1,185.86.

Smith & Nephew Trading Up 1.0%

Shares of LON SN opened at GBX 1,159 on Thursday. The stock’s 50 day simple moving average is GBX 1,236.09 and its 200-day simple moving average is GBX 1,258.20. The stock has a market capitalization of £12.71 billion, a price-to-earnings ratio of 41.73, a price-to-earnings-growth ratio of 0.46 and a beta of 0.74. The company has a quick ratio of 0.84, a current ratio of 2.57 and a debt-to-equity ratio of 62.90.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.